Study of donor immune cells after stem cell transplant for AML/MDS
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether infusing donor immune cells after a stem cell transplant can help treat AML or MDS. It involves donating and receiving a specific type of immune-cell infusion, with safety checks around the donor’s procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and have AML or MDS
- You must have had a stem cell transplant using PBSC (peripheral blood stem cells)
- The donor must be 18 years or older
- Both you and your donor must give informed consent to join the study
- Your donor must not need a central line (a larger vein access tube) for the donor blood-collection procedure (leukapheresis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
This study tests whether giving donor immune cells earlier or later after a stem cell transplant helps prevent relapse in people with tough-to-treat leukemia or MDS. Participants must be in remission one month after transplant.
This trial is testing a new way to treat blood cancers that have come back after a stem cell transplant and haven't responded to standard donor cell therapy. The treatment uses special immune cells that are modified to avoid attacking the body, which may help fight the cancer without causing graft-versus-host disease.
This study tests whether giving extra immune cells (called DLI) before or after a stem cell transplant can help prevent or treat leukemia relapse. These cells come from the same family member who donated your transplant, and the study also asks the donor to do some exercise sessions beforehand.
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
Hear when a new AML/MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.